Bivalirudin Injection, Powder, Lyophilized, For Solution
Product Images NDC 0781-3158

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Bivalirudin (NDC 0781-3158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Bivalirudin 01)

Chemical structure diagram of the active ingredient bivalirudin, showing its detailed molecular components including amino acid residues and functional groups, as part of its lyophilized powder form for injection.*

FDA Label Image

Vial Label (Bivalirudin 02)

Packaging label for Bivalirudin for Injection 250 mg by Sandoz Inc. The label indicates the product is for intravenous use only and contains 10 single-dose vials. Each vial contains 250 mg bivalirudin equivalent to 275 mg bivalirudin trifluoroacetate, lyophilized powder for solution with instructions to add 5 mL of sterile water for injection. The label includes storage information, barcodes, and patent details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.